Key result
Once-weekly IcoSema improves glycemic control, weight loss, and hypoglycemia risk over daily IDegLira in T2D.
Why the study?
Does once-weekly IcoSema improve glycaemic control and reduce hypoglycaemia risk in adults with T2D requiring insulin intensification compared to once-daily IDegLira?
Meta-Analysis
Does once-weekly IcoSema improve glycaemic control and reduce hypoglycaemia risk in adults with T2D requiring insulin intensification compared to once-daily IDegLira?
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Once-weekly IcoSema offers an efficacious treatment option that improves glycaemic control and reduces treatment burden compared to once-daily IDegLira in adults with T2D.
These results indicate that once-weekly IcoSema is an efficacious treatment option for adults with T2D requiring insulin intensification. IcoSema was associated with improved glycaemic control, weight reduction, and lower hypoglycaemia risk compared with once-daily IDegLira, as well as a reduction in insulin and injection requirements. Weekly IcoSema offers the potential to reduce treatment burden and increase adherence, thereby improving long-term disease control and patient outcomes.
Kandalam et al. (2026) conducted a meta-analysis in Type 2 Diabetes. IcoSema vs. Once-daily IDegLira was evaluated. Once-weekly IcoSema was associated with improved glycaemic control, weight reduction, and lower hypoglycaemia risk compared with once-daily IDegLira in adults with type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: